PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26885050-6	2015	In this study, we showed Dex inhibited the increase in cTnI and CK-MB, attenuated the production of pro-inflammatory cytokines TNF-alpha, IL-6 and IL-8, and promoted anti-inflammatory cytokine IL-10 production.	Dexmedetomidine	25-28	interleukin 10	Homo sapiens	193-198	
23582761-9	2013	According to our in vitro and in vivo results, dexmedetomidine shows anti-inflammatory effect by increasing IL-4 and IL-10 levels responsible from anti-inflammatory response via Th2 pathway.	Dexmedetomidine	47-62	interleukin 10	Homo sapiens	117-122	
35545412-22	2022	CONCLUSIONS: Intraoperative dexmedetomidine infusion can reduce the incidence of POCD and POD in elderly patients undergoing hepatic lobectomy, and the protective mechanism appears to involve the down-regulation of TNF-alpha and IL-1beta and upregulation of IL-10 expression, which lead to rebalance between proinflammation and anti-inflammation.	Dexmedetomidine	28-43	interleukin 10	Homo sapiens	258-263	
22824921-18	2013	DEX delayed postoperative rise in IL-10 but not in IL-6 or IL-8.	Dexmedetomidine	0-3	interleukin 10	Homo sapiens	34-39	
34744722-11	2021	Conclusion: Taken together, our study indicates that combination of DXM and TMD effectively lowers blood pressure and reduces inflammation through increasing the level of IL-10, reducing CRP and inhibiting p-p38/MAPK in patients with PIH.	Dexmedetomidine	68-71	interleukin 10	Homo sapiens	171-176	
33641076-4	2021	In vivo, Dex markedly reduced pulmonary edema induced by LPS through promoting AFC, prevented LPS-induced downregulation of alpha-, beta-, and gamma-ENaC expression, attenuated inflammatory cell infiltration in lung tissue, reduced the concentrations of TNF-alpha, IL-1beta, and IL-6, and increased concentrations of IL-10 in bronchoalveolar lavage fluid (BALF).	Dexmedetomidine	9-12	interleukin 10	Homo sapiens	317-322	
33747166-6	2021	In comparison with the control group, patients in the Dex group exhibited a significant increase in cardiac function, as indicated by an increase in HR, MAP and IL-10 levels, and a significant decrease in cTnI, IL-8, MDA and glucose levels.	Dexmedetomidine	54-57	interleukin 10	Homo sapiens	161-166	
33331570-7	2020	Compared with the control group, in the Dex group at T1, T2, and T3, the serum creatine kinase-MB, cardiac troponin-I, C-reactive protein, and tumor necrosis factor-alpha levels were decreased, and the interleukin-10 level, the serum total superoxide dismutase, and total anti-oxidant capability increased, while the myeloperoxidase and malondialdehyde levels decreased (all P < 0.05).	Dexmedetomidine	40-43	interleukin 10	Homo sapiens	202-216	
32343308-6	2020	The simultaneous administration of DEX and sufentanil significantly reduced plasma IL-6 and TNF-alpha concentrations and increased IL-10 level (P < 0.0001, P = 0.0003, and P = 0.0345, respectively), accompanied by better postoperative delirium categories and health statuses of patients (P = 0.024 and P < 0.05, respectively).	Dexmedetomidine	35-38	interleukin 10	Homo sapiens	131-136	
31668347-5	2019	DEX infusion during the perioperative period inhibited release of epinephrine, norepinephrine, and cortisol; decreased blood glucose, interleukin (IL)-6, tumour necrosis factor-alpha, and C-reactive protein; and increased interleukin-10 in surgical patients.	Dexmedetomidine	0-3	interleukin 10	Homo sapiens	222-236